With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ:MRSN) with a Buy rating and a price target of $12. The analyst says the…
Mersana Inks Cancer Therapy Development Deal With Merck Germany
Mersana Therapeutics Inc (NASDAQ:MRSN) signed a deal for developing antibody-drug conjugates (ADCs) for cancer treatment with Germany’s Merck KGaA (OTC:MKGAF) (OTC:MKKGY). Mersana would…
Germany’s Merck To Launch Semiconductor Base In China
German semiconductor supplier of chemicals and materials Merck KGaA (OTC:MKKGY) forged a contract with local authorities to open a semiconductor…
TSMC Looks To Hire Over 8,000 People In 2022
Taiwan’s top two chipmakers plan to hire over 10,000 engineers in 2022 to bolster their aggressive expansion plans and maintain their technological edge,
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche’s Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
Merck KGaA (OTC:MKGAF) and GlaxoSmithKline Plc (NASDAQ:GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said the move was…
Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
Merck KGaA’s (OTC:MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring…
Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share
Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of…
UK’s NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA’s Bavencio As First-Line Therapy For Bladder Cancer
England’s drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE) and Merck KGaA’s (OTC:MKGAF) Bavencio (avelumab) as first-line maintenance therapy for…